Novartis Buys Start-Up Amblyotech To Beat ‘Lazy Eye’ Condition With Gaming Technology
Executive Summary
Novartis announced it acquired digital therapeutics company Amblyotech, which uses gaming technology with 3-D glasses to help treat lazy eye.
You may also be interested in...
Seeing Is Believing: New Approaches For Treating Eye Disorders
Developers of new ophthalmic products are thinking outside of the box. A raft of new gene therapies are progressing in the clinic, including a gene therapy paired with biomimetic goggles. Elsewhere, technology players are partnering with traditional biopharmaceutical companies and bringing algorithms, machine learning and microelectronics to bear on eye disorders and disease diagnostics.
Getting Personal With Brittany Barreto: From One-Time ‘Science Hater’ To Genetics Doctorate, DNA Dating App And Women’s Health Champion
Medtech Insight sat down with Brittany Barreto, CEO of FemHealth Insights, who participated in a panel discussion at SXSW 2023 on the $1t femtech industry, to talk about her journey to becoming a women’s health care champion.
Becton Dickinson Receives FDA Clearance For Vaginal Panel To Detect Vaginitis
BD said its newly FDA-cleared Vaginal Panel can detect three most common infectious causes of vaginitis with a single swab, reducing the need for repeat testing.